These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 10843460)

  • 1. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.
    Bearden DT; Rodvold KA
    Clin Pharmacokinet; 2000 May; 38(5):415-26. PubMed ID: 10843460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of obesity on pharmacokinetics implications for drug therapy.
    Cheymol G
    Clin Pharmacokinet; 2000 Sep; 39(3):215-31. PubMed ID: 11020136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial dosing in obese patients.
    Wurtz R; Itokazu G; Rodvold K
    Clin Infect Dis; 1997 Jul; 25(1):112-8. PubMed ID: 9243045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of drugs in obesity. An update.
    Cheymol G
    Clin Pharmacokinet; 1993 Aug; 25(2):103-14. PubMed ID: 8403734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
    Roberts JA; Lipman J
    Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of elevated trough serum vancomycin concentrations with obesity.
    Richardson J; Scheetz M; O'Donnell EP
    J Infect Chemother; 2015 Jul; 21(7):507-11. PubMed ID: 25851852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.
    Alobaid AS; Hites M; Lipman J; Taccone FS; Roberts JA
    Int J Antimicrob Agents; 2016 Apr; 47(4):259-68. PubMed ID: 26988339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing of vancomycin in patients with continuous-flow left ventricular assist devices: a clinical pharmacokinetic analysis.
    Jennings DL; Makowski CT; Chambers RM; Lanfear DE
    Int J Artif Organs; 2014 Mar; 37(3):270-4. PubMed ID: 24619894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of obesity on the pharmacokinetics of drugs in humans.
    Hanley MJ; Abernethy DR; Greenblatt DJ
    Clin Pharmacokinet; 2010; 49(2):71-87. PubMed ID: 20067334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of anti-infective agents in paediatric patients.
    Butler DR; Kuhn RJ; Chandler MH
    Clin Pharmacokinet; 1994 May; 26(5):374-95. PubMed ID: 8055682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of antibacterial drugs in neonates.
    Paap CM; Nahata MC
    Clin Pharmacokinet; 1990 Oct; 19(4):280-318. PubMed ID: 2208898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations.
    Henry SL; Galloway KP
    Clin Pharmacokinet; 1995 Jul; 29(1):36-45. PubMed ID: 7586897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial dosing considerations in obese adult patients.
    Pai MP; Bearden DT
    Pharmacotherapy; 2007 Aug; 27(8):1081-91. PubMed ID: 17655508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosage adjustment of antiinfective therapy in patients with renal impairment.
    Eckhardt A; Borner K; Keller F; Zellner D
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):99-102. PubMed ID: 9088997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug disposition in obese humans. An update.
    Abernethy DR; Greenblatt DJ
    Clin Pharmacokinet; 1986; 11(3):199-213. PubMed ID: 3524955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies.
    Durand C; Bylo M; Howard B; Belliveau P
    Ann Pharmacother; 2018 Jun; 52(6):580-590. PubMed ID: 29262697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues.
    Williams DN; Raymond JL
    Clin Pharmacokinet; 1998 Jul; 35(1):65-77. PubMed ID: 9673835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years.
    Grace E
    J Antimicrob Chemother; 2012 Jun; 67(6):1305-10. PubMed ID: 22382471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
    Morrill HJ; Caffrey AR; Noh E; LaPlante KL
    Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.